Background

Many small-molecule CDC7 inhibitors have been developed as the focus of multiple drug discovery programs in oncology as an alternative strategy to restrain DNA replication in cancer.

There are a number of CDC7 kinase inhibitors in development as an anti-cancer treatment and many are in clinical trial. However, problems persist in this approach where there are ongoing issues with reaching a good level of efficacy whilst avoiding toxicity of these CDC7 kinase inhibitors. In particular, dose-limiting tolerability issues have been observed with some inhibitors leading to their clinical trial termination.

Thus, there is an unmet need for improving the efficacy and tolerability of CDC7 kinase inhibitors.